Drug
Immunotherapy
CI-DRUG-00000300Explore in graph →NCIt C15262 CIViC
Regulatory
Approvals (0)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
Data not yet available
No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.
What CancerIndex knows
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Phase3 | Phase 3 | 41 | 28 | 13 | 61 | 0 | — | — | Jan 1, 2002 |
| Malignant Lung Neoplasm | Phase3 | Phase 3 | 10 | 7 | 4 | 22 | 0 | — | — | Mar 10, 2017 |
| Malignant Esophageal Neoplasm | Phase3 | Phase 3 | 8 | 8 | 3 | 8 | 0 | — | — | Jan 1, 2002 |
| Malignant Rectal Neoplasm | Phase3 | Phase 3 | 3 | 0 | 1 | 4 | 0 | — | — | Nov 1, 2019 |
| Cutaneous Melanoma | Phase3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — |
Curated evidence
Clinical evidence (3)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 33972172
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| High2 | ||||||||
| Immunotherapy | Lung Non-Small Cell Carcinoma | |||||||
Clinical trials
Trials with this intervention (94)
Most recently updated first, 50 per page.
clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06878222 | Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC | recruiting | Phase 2 | 35 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT04612309 | Retrospective Study on the Use of Immunotherapy in Patients With MSI-H Metastatic Colorectal Cancer(C-MSI) |